Aurinia Enhances Research, Development, & Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors
February 22 2018 - 3:07PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia”
or the “Company”), a clinical stage biopharmaceutical company
focused on the global immunology market, today announced the
appointment of Michael Hayden, CM OBC MB ChB PhD FRCP (C) FRSC to
its board of directors. Dr. Hayden was most recently the President
of Global R&D and Chief Scientific Officer at Teva.
“Michael’s scientific acumen and clinical development track
record is unparalleled in this industry,” said Richard M. Glickman,
Chief Executive Officer and Chairman of the Board of Aurinia. “His
skillset rounds out our board with world class research and
development experience which will prove extremely valuable as we
initiate our new indications and assess strategic growth options
for Aurinia.”
Dr. Hayden was recently named one of the 50 Canadians born in
the 20th century who have changed the world. He is the co-founder
of three biotechnology companies: NeuroVir Therapeutics Inc., Xenon
Pharmaceuticals Inc., and Aspreva Pharmaceuticals Corp. Dr. Hayden
sits on different boards including Xenon Pharmaceuticals and
Lycera. Author of over 860 peer-reviewed publications and invited
submissions, Dr. Hayden has focused his research primarily on
genetic diseases, including genetics of diabetes, lipoprotein
disorders, Huntington disease, predictive and personalized
medicine. Dr. Hayden was inducted into the Canadian Medical Hall of
Fame in 2017. He was named one of PharmaVoice’s “100 of the Most
Inspiring People” (2015); awarded an Honorary Doctor of Science by
the University of Gottingen (2014); the Luminary award by the
Personalized Medicine World Conference (2014); and the Diamond
Jubilee Medal (2012), on behalf of HRH Queen Elisabeth II, in
recognition of his significant contributions and achievements. Dr.
Hayden has also been awarded the Order of Canada (2011), and the
Order of British Columbia (2010). He was named Canada’s Health
Researcher of the Year by CIHR (NIH of Canada) in 2008, and he
received the Prix Galien in 2007, which recognizes the outstanding
contribution of a researcher to Canadian pharmaceutical
research.
"I hope to build upon the success we created as a team at
Aspreva in improving the treatment paradigm for lupus nephritis,
said Dr. Hayden. “Aurinia’s commitment to addressing the
significant unmet medical need in lupus nephritis is highly
encouraging for patients, and I look forward to once again working
alongside this exceptional management team as we pursue a
successful future for the company.”
Forward Looking StatementsThis press release contains
forward-looking statements, including statements related to
Aurinia’s corporate strategy and Dr. Hayden’s expected impact on
Aurinia’s progress. It is possible that such results or conclusions
may change based on further analyses of these data. Words such as
"plans," "intends," “may,” "will," "believe," and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Aurinia’s current
expectations. Forward-looking statements involve risks and
uncertainties. Aurinia’s actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the risk that
Aurinia’s analyses, assessment and conclusions of the results of
its clinical studies may change based on further analyses, the risk
that Aurinia will not successfully complete its clinical programs
and the risk that Aurinia’s clinical studies for voclosporin may
not lead to regulatory approval. These and other risk factors are
discussed under "Risk Factors" and elsewhere in Aurinia’s Annual
Information Form for the year ended December 31, 2016 filed with
Canadian securities authorities and available at www.sedar.com and
on Form 40-F with the U.S. Securities Exchange Commission and
available at www.sec.gov, each as updated by subsequent filings,
including filings on Form 6-K. Aurinia expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Aurinia's expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statements are based, except as required by law.
We seek safe harbor.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180222006483/en/
Aurinia Pharmaceuticals Inc.Investor Contact:Celia
EconomidesVP, Corporate & Public
AffairsIR@auriniapharma.comorMedia:Christopher Hippolyte,
212-364-0458Christopher.hippolyte@inventivhealth.com